StockData
Amylyx Pharmaceuticals, Inc. logo

Amylyx Pharmaceuticals, Inc. (AMLX) stock

AMLXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30
$27.52−0.28 (-1.01%)

Close on Nov 17, 2026Market cap $3.07BP/E –Yield –

Amylyx Pharmaceuticals gross margin

Gross margin is gross profit as a percentage of revenue.

Amylyx Pharmaceuticals's gross margin for the twelve months ending Sep 30, 2024 was 92.2%. For fiscal 2024 it was 93.2%, against 93.3% the year before.

Annual gross margin

PeriodPeriod endValueChange (pts)
FY2024Dec 31, 202493.2%−0.1
FY2023Dec 31, 202393.3%+6.8
FY2022Dec 31, 202286.5%–

Quarterly gross margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q3 FY2024Sep 30, 2024100.0%+5.7
Q1 FY2024Mar 31, 202493.3%+0.7
Q4 FY2023Dec 31, 202391.4%+4.3
Q3 FY2023Sep 30, 202394.9%+44.8
Q2 FY2023Jun 30, 202394.3%–
Q1 FY2023Mar 31, 202392.6%–
Q4 FY2022Dec 31, 202287.1%–
Q3 FY2022Sep 30, 202250.1%–

More Amylyx Pharmaceuticals figures

See a number that looks wrong?